Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma.

Bastholt L, Schmidt H, Bjerregaard JK, Herrstedt J, Svane IM.

Eur J Cancer. 2019 Aug 20;119:122-131. doi: 10.1016/j.ejca.2019.06.022. [Epub ahead of print]

PMID:
31442816
2.

The real-world outcome of metastatic melanoma: Unknown primary vs. known cutaneous.

Ellebaek E, Bastholt L, Schmidt H, Svane IM, Donia M.

Int J Cancer. 2019 Aug 19. doi: 10.1002/ijc.32631. [Epub ahead of print] No abstract available.

PMID:
31423583
3.

Real-world evidence to guide healthcare policies in oncology.

Donia M, Hansen SW, Svane IM.

Oncotarget. 2019 Jul 16;10(44):4513-4515. doi: 10.18632/oncotarget.27077. eCollection 2019 Jul 16.

4.

Empty peptide-receptive MHC class I molecules for efficient detection of antigen-specific T cells.

Saini SK, Tamhane T, Anjanappa R, Saikia A, Ramskov S, Donia M, Svane IM, Jakobsen SN, Garcia-Alai M, Zacharias M, Meijers R, Springer S, Hadrup SR.

Sci Immunol. 2019 Jul 19;4(37). pii: eaau9039. doi: 10.1126/sciimmunol.aau9039.

PMID:
31324690
5.

B-cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon-α2, or combination treatment.

Sørensen AL, Bjørn ME, Riley CH, Holmstrøm M, Andersen MH, Svane IM, Mikkelsen SU, Skov V, Kjaer L, Hasselbalch HC, Nielsen CH.

Eur J Haematol. 2019 Jul 11. doi: 10.1111/ejh.13292. [Epub ahead of print]

PMID:
31297883
6.

[Immunotherapy for patients with malignant melanoma and brain metastases].

Simonsen LT, Schmidt AMS, Øllegaard TH, Svane IM, Bastholt L, Luczak AA, Schmidt H.

Ugeskr Laeger. 2019 Jun 10;181(24). pii: V01190057. Danish.

PMID:
31267950
7.

MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.

Peeters MJW, Dulkeviciute D, Draghi A, Ritter C, Rahbech A, Skadborg SK, Seremet T, Carnaz Simões AM, Martinenaite E, Halldórsdóttir HR, Andersen MH, Olofsson GH, Svane IM, Rasmussen LJ, Met Ö, Becker JC, Donia M, Desler C, Thor Straten P.

Cancer Immunol Res. 2019 Sep;7(9):1472-1484. doi: 10.1158/2326-6066.CIR-18-0841. Epub 2019 Jul 2.

PMID:
31266785
8.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma.

Ascierto PA, Ferrucci PF, Fisher R, Del Vecchio M, Atkinson V, Schmidt H, Schachter J, Queirolo P, Long GV, Di Giacomo AM, Svane IM, Lotem M, Bar-Sela G, Couture F, Mookerjee B, Ghori R, Ibrahim N, Moreno BH, Ribas A.

Nat Med. 2019 Jun;25(6):941-946. doi: 10.1038/s41591-019-0448-9. Epub 2019 Jun 6.

PMID:
31171878
9.

High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort.

Bastholt L, Svane IM, Bjerregaard JK, Herrstedt J, Hróbjartsson A, Schmidt H.

Eur J Cancer. 2019 Jul;115:61-67. doi: 10.1016/j.ejca.2019.03.023. Epub 2019 May 17.

PMID:
31108244
10.

Peripheral memory T cells specific for Arginase-1.

Martinenaite E, Ahmad SM, Svane IM, Andersen MH.

Cell Mol Immunol. 2019 Aug;16(8):718-719. doi: 10.1038/s41423-019-0231-3. Epub 2019 May 10. No abstract available.

PMID:
31076727
11.

Peptide Super-Agonist Enhances T-Cell Responses to Melanoma.

Galloway SAE, Dolton G, Attaf M, Wall A, Fuller A, Rius C, Bianchi V, Theaker S, Lloyd A, Caillaud ME, Svane IM, Donia M, Cole DK, Szomolay B, Rizkallah P, Sewell AK.

Front Immunol. 2019 Mar 13;10:319. doi: 10.3389/fimmu.2019.00319. eCollection 2019.

12.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppen MH, Hoejberg L, Schmidt H, van Thienen JV, Haanen JBAG, Tiainen L, Svane IM, Mäkelä S, Seremet T, Arance A, Dummer R, Bastholt L, Nyakas M, Straume O, Menzies AM, Long GV, Atkinson V, Blank CU, Neyns B.

Ann Oncol. 2019 Jul 1;30(7):1154-1161. doi: 10.1093/annonc/mdz110.

PMID:
30923820
13.

Correction: Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Apr;120(8):870. doi: 10.1038/s41416-019-0425-6.

14.

[Cancer immune therapy for the treatment of haematological malignancies].

Holmström MO, Klausen U, Jørgensen NG, Holmberg S, Grauslund J, Met Ö, Svane IM, Pedersen LM, Knudsen LM, Hasselbalch HC, Andersen MH.

Ugeskr Laeger. 2019 Mar 4;181(10). pii: V06180421. Danish.

PMID:
30869069
15.

Collagen density regulates the activity of tumor-infiltrating T cells.

Kuczek DE, Larsen AMH, Thorseth ML, Carretta M, Kalvisa A, Siersbæk MS, Simões AMC, Roslind A, Engelholm LH, Noessner E, Donia M, Svane IM, Straten PT, Grøntved L, Madsen DH.

J Immunother Cancer. 2019 Mar 12;7(1):68. doi: 10.1186/s40425-019-0556-6.

16.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.

J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.

17.

Tumour-reactive T cell subsets in the microenvironment of ovarian cancer.

Westergaard MCW, Andersen R, Chong C, Kjeldsen JW, Pedersen M, Friese C, Hasselager T, Lajer H, Coukos G, Bassani-Sternberg M, Donia M, Svane IM.

Br J Cancer. 2019 Feb;120(4):424-434. doi: 10.1038/s41416-019-0384-y. Epub 2019 Feb 5. Erratum in: Br J Cancer. 2019 Apr;120(8):870.

PMID:
30718808
18.

High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.

Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, Martinenaite E, Riley CH, Svane IM, Kjær L, Skov V, Ellervik C, Pallisgaard N, Hasselbalch HC, Andersen MH.

Blood Cancer J. 2019 Jan 17;9(2):8. doi: 10.1038/s41408-018-0166-4.

19.

HER2 CAR-T Cells Eradicate Uveal Melanoma and T-cell Therapy-Resistant Human Melanoma in IL2 Transgenic NOD/SCID IL2 Receptor Knockout Mice.

Forsberg EMV, Lindberg MF, Jespersen H, Alsén S, Bagge RO, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA.

Cancer Res. 2019 Mar 1;79(5):899-904. doi: 10.1158/0008-5472.CAN-18-3158. Epub 2019 Jan 8.

PMID:
30622115
20.

The real-world impact of modern treatments on the survival of patients with metastatic melanoma.

Donia M, Ellebaek E, Øllegaard TH, Duval L, Aaby JB, Hoejberg L, Køhler UH, Schmidt H, Bastholt L, Svane IM.

Eur J Cancer. 2019 Feb;108:25-32. doi: 10.1016/j.ejca.2018.12.002. Epub 2018 Dec 31.

PMID:
30605822
21.

Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs.

Draghi A, Borch TH, Radic HD, Chamberlain CA, Gokuldass A, Svane IM, Donia M.

Int J Cancer. 2019 Sep 1;145(5):1408-1413. doi: 10.1002/ijc.32080. Epub 2019 Jan 7.

PMID:
30575963
22.

Non-invasive biomarkers derived from the extracellular matrix associate with response to immune checkpoint blockade (anti-CTLA-4) in metastatic melanoma patients.

Jensen C, Madsen DH, Hansen M, Schmidt H, Svane IM, Karsdal MA, Willumsen N.

J Immunother Cancer. 2018 Dec 19;6(1):152. doi: 10.1186/s40425-018-0474-z.

23.

Immunoprofiles of colorectal cancer from Lynch syndrome.

Walkowska J, Kallemose T, Jönsson G, Jönsson M, Andersen O, Andersen MH, Svane IM, Langkilde A, Nilbert M, Therkildsen C.

Oncoimmunology. 2018 Sep 26;8(1):e1515612. doi: 10.1080/2162402X.2018.1515612. eCollection 2019.

24.

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.

Pedersen M, Westergaard MCW, Milne K, Nielsen M, Borch TH, Poulsen LG, Hendel HW, Kennedy M, Briggs G, Ledoux S, Nøttrup TJ, Andersen P, Hasselager T, Met Ö, Nelson BH, Donia M, Svane IM.

Oncoimmunology. 2018 Sep 26;7(12):e1502905. doi: 10.1080/2162402X.2018.1502905. eCollection 2018.

PMID:
30524900
25.

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Hölmich LR, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2018 Nov 9;9(88):35870. doi: 10.18632/oncotarget.26359. eCollection 2018 Nov 9.

26.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514.

PMID:
30422243
27.

Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies.

Klausen U, Holmberg S, Holmström MO, Jørgensen NGD, Grauslund JH, Svane IM, Andersen MH.

Front Immunol. 2018 Oct 1;9:2264. doi: 10.3389/fimmu.2018.02264. eCollection 2018. Review.

28.

Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report.

Kjeldsen JW, Iversen TZ, Engell-Noerregaard L, Mellemgaard A, Andersen MH, Svane IM.

Front Immunol. 2018 Sep 19;9:2145. doi: 10.3389/fimmu.2018.02145. eCollection 2018.

29.

Principles of adoptive T cell therapy in cancer.

Met Ö, Jensen KM, Chamberlain CA, Donia M, Svane IM.

Semin Immunopathol. 2019 Jan;41(1):49-58. doi: 10.1007/s00281-018-0703-z. Epub 2018 Sep 5. Review.

PMID:
30187086
30.

Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, Andersen MH.

Oncoimmunology. 2018 Feb 27;7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018.

31.

[Cancer immunotherapy].

Kjeldsen JW, Donia M, Svane IM.

Ugeskr Laeger. 2018 May 21;180(21). pii: V09170691. Review. Danish.

PMID:
29804567
32.

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab.

Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, Nielsen CH.

Oncoimmunology. 2018 Feb 1;7(5):e1424674. doi: 10.1080/2162402X.2018.1424674. eCollection 2018.

33.

T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.

Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, Donia M.

Ann Oncol. 2018 Jul 1;29(7):1575-1581. doi: 10.1093/annonc/mdy139.

PMID:
29688262
34.

Cancer immunotherapy in patients with brain metastases.

Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, Donia M.

Cancer Immunol Immunother. 2018 May;67(5):703-711. doi: 10.1007/s00262-018-2146-8. Epub 2018 Mar 8. Review.

PMID:
29520474
35.

Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations.

Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM, Ott S, Connor T, Szomolay B, Dolton G, Sewell AK.

J Immunol. 2018 Apr 1;200(7):2263-2279. doi: 10.4049/jimmunol.1700242. Epub 2018 Feb 26.

36.

Frequent adaptive immune responses against arginase-1.

Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager Jørgensen N, Met Ö, Donia M, Svane IM, Andersen MH.

Oncoimmunology. 2017 Dec 26;7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018.

37.

The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M, Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, Andersen MH.

Oncoimmunology. 2017 Nov 1;7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018.

38.

T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy.

Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B, Kromann-Andersen B, Hasselager T, Donia M, Svane IM.

Cancer Immunol Res. 2018 Feb;6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. Epub 2018 Jan 4.

39.

Checkpoint inhibitors in breast cancer - Current status.

Polk A, Svane IM, Andersson M, Nielsen D.

Cancer Treat Rev. 2018 Feb;63:122-134. doi: 10.1016/j.ctrv.2017.12.008. Epub 2017 Dec 14. Review.

PMID:
29287242
40.

Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma.

Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T, Kvist A, Ringnér M, Svane IM, Jönsson G.

Nat Commun. 2017 Nov 23;8(1):1738. doi: 10.1038/s41467-017-01460-0.

41.

Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma.

Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, Svane IM.

Stem Cell Investig. 2017 Sep 21;4:77. doi: 10.21037/sci.2017.08.06. eCollection 2017.

42.

[Immunotherapy is cancer treatment with a novel side-effect profile].

Kondrup M, Raunkilde L, Svane IM, Schmidt H, Bastholt L.

Ugeskr Laeger. 2017 Oct 2;179(40). pii: V05170365. Review. Danish.

PMID:
28992844
43.

Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.

Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG.

Oncotarget. 2017 Jun 27;8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017 Sep 15.

44.

Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.

Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA.

Nat Commun. 2017 Sep 27;8(1):707. doi: 10.1038/s41467-017-00786-z.

45.

Predictors of responses to immune checkpoint blockade in advanced melanoma.

Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, Zitvogel L.

Nat Commun. 2017 Sep 19;8(1):592. doi: 10.1038/s41467-017-00608-2.

46.

Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes.

Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov V, Hasselbalch HC.

Leuk Lymphoma. 2018 Apr;59(4):973-977. doi: 10.1080/10428194.2017.1359743. Epub 2017 Aug 9. No abstract available.

PMID:
28792253
47.

PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer.

Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S, Dolton G, Lyngaa R, Hadrup SR, Sewell AK, Svane IM.

Clin Cancer Res. 2017 Oct 1;23(19):5779-5788. doi: 10.1158/1078-0432.CCR-16-1692. Epub 2017 Jul 5.

48.

The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy.

Holmström MO, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM, Hasselbalch HC, Andersen MH.

Leukemia. 2018 Feb;32(2):429-437. doi: 10.1038/leu.2017.214. Epub 2017 Jul 5.

PMID:
28676668
49.

Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.

Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM.

Cancer Res. 2017 Sep 1;77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. Epub 2017 Jun 27.

50.

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.

Bjoern J, Lyngaa R, Andersen R, Hölmich LR, Hadrup SR, Donia M, Svane IM.

Oncotarget. 2017 Apr 18;8(16):27062-27074. doi: 10.18632/oncotarget.16003. Erratum in: Oncotarget. 2018 Nov 9;9(88):35870. Rosenkrantz, Lisbet Hölmich [corrected to Hölmich, Lisbet Rosenkrantz].

Supplemental Content

Loading ...
Support Center